USPTO Examiner COFFA SERGIO - Art Unit 1658

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19217808METHODS OF USING A GIP/GLP1 CO-AGONIST FOR THERAPYMay 2025March 2026Allow921YesNo
19174121SEMAGLUTIDE IN MEDICAL THERAPYApril 2025December 2025Allow820NoNo
19023048PHARMACEUTICAL COMPOSITIONS COMPRISING NOVEL CYCLIC PEPTIDESJanuary 2025April 2025Allow310YesNo
18820792SEMAGLUTIDE IN MEDICAL THERAPYAugust 2024February 2025Allow520NoNo
18754189CYCLOPHILIN INHIBITORS AND USES THEREOFJune 2024September 2025Allow1411NoNo
18724136IL-4 DERIVED PEPTIDE FRAGMENTS FOR USE IN THE TREATMENT OF DIABETIC NEPHROPATHYJune 2024June 2025Allow1220NoNo
18751723NPY2 RECEPTOR AGONISTSJune 2024May 2025Allow1101NoNo
18736608SEMAGLUTIDE IN MEDICAL THERAPYJune 2024January 2025Abandon700NoNo
18734820PEPTIDES, HYDROGEL COMPOSITIONS AND METHODS OF USE THEREOFJune 2024July 2025Allow1311NoNo
18666750STAPLED AND SPECIFICALLY TARGETED ANTIMICROBIAL PEPTIDEMay 2024November 2024Allow611NoNo
18660504NOVEL PEPTIDESMay 2024August 2024Allow300NoNo
18661201HUMAN AMYLIN ANALOG POLYPEPTIDES AND METHODS OF USEMay 2024October 2025Allow1711NoNo
18639139ANTIFUNGAL PROTEIN COMPOSITIONApril 2024February 2026Abandon2201NoNo
18627757COMPOUNDS FOR USE AS APELIN RECEPTOR ANTAGONISTSApril 2024September 2025Allow1811YesNo
18615134METHODS AND COMPOSITIONS FOR TREATING MUCOSAL TISSUE DISORDERSMarch 2024March 2026Allow2411NoNo
18423020ANTI-KRAS-G12D T CELL RECEPTORSJanuary 2024April 2025Allow1511NoNo
18415952BIOLOGICAL ACTIVE PEPTIDE FOR IMPROVING ENZYME ACTIVITY OF ACE2 AND APPLICATION THEREOFJanuary 2024January 2025Allow1220NoNo
18540193URI Agonist/VasodilatorDecember 2023February 2026Allow2631YesNo
18494623SELECTIVE TARGETING OF APOPTOSIS PROTEINS BY STRUCTURALLY-STABILIZED AND/OR CYSTEINE-REACTIVE NOXA PEPTIDESOctober 2023July 2025Allow2011NoNo
18492612PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASESOctober 2023November 2025Allow2421NoNo
18483123MODIFIED PEPTIDES AND ASSOCIATED METHODS OF USEOctober 2023October 2025Allow2421YesNo
18476860BCL9 PEPTIDES AND VARIANTS THEREOFSeptember 2023July 2025Abandon2211NoNo
18474843AGENT FOR PROMOTING ANGIOGENESIS AND METHODS AND USES THEREOFSeptember 2023November 2025Abandon2601NoNo
18471220REGENERATIVE POLYPEPTIDES AND USES THEREOFSeptember 2023December 2024Abandon1521NoNo
18363448MATERIALS AND METHODS FOR IMPROVING GASTROINTESTINAL FUNCTIONAugust 2023October 2024Allow1511NoNo
18212119COMPOSITIONS AND METHODS FOR IMPROVING BRUISING AND REJUVENATING SKINJune 2023September 2024Allow1521YesNo
18334309INTERLEUKIN-13 BINDING CYCLIC OLIGOPEPTIDES AND METHODS OF USE THEREOFJune 2023August 2024Allow1411NoNo
18321472IL-2R-BETA-GAMMA BINDING COMPOUNDSMay 2023November 2024Abandon1701NoNo
18299600MASP INHIBITORY COMPOUNDS AND USES THEREOFApril 2023July 2025Allow2831NoNo
18176013ALK POLYPEPTIDES AND METHODS OF USE THEREOFFebruary 2023March 2025Allow2531NoNo
18112468Ocular Compositions and Methods ThereofFebruary 2023November 2025Allow3241YesNo
18170163USE OF PAYCS IN REGULATION OF INTESTINAL FLORA, METABOLITES, AND BRAIN NEUROTRANSMITTERSFebruary 2023July 2024Allow1721NoNo
18164297NOVEL MUTANT BACTERIORHODOPSIN-LIKE-CHANNELRHODOPSIN ION CHANNELFebruary 2023January 2026Allow3651YesNo
18105752FORMULATIONS WITH REDUCED OXIDATIONFebruary 2023February 2026Abandon3641YesYes
18163210Regenerative Polypeptides and Uses ThereofFebruary 2023April 2024Abandon1401NoNo
18160513TREATMENT OF RESPIRATORY TRACT DISEASES AND INFECTIONS WITH ASCORBIC ACID COMPOSITIONSJanuary 2023June 2025Allow2812NoNo
18100032SOLID STATE FORMS OF VOCLOSPORINJanuary 2023December 2024Allow2310NoNo
18146779THERAPEUTIC PEPTIDESDecember 2022May 2025Abandon2821NoNo
18068641NPY2 RECEPTOR AGONISTSDecember 2022April 2024Allow1511NoNo
18077902SYNTHESIS OF ECHINOCANDIN ANTIFUNGAL AGENTDecember 2022August 2024Allow2111NoNo
18076759PROMOTING TRAINED IMMUNITY WITH THERAPEUTIC NANOBIOLOGIC COMPOSITIONSDecember 2022December 2024Abandon2411NoNo
17991219CCN3 AND CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USENovember 2022February 2024Allow1511NoNo
17998366PEPTIDE FOR USE IN THE PREVENTION AND/OR TREATMENT OF A DISEASE CAUSED BY A VIRUS AFFECTING THE RESPIRATORY TRACTNovember 2022November 2025Allow3610NoNo
18054261MACROCYCLIC POLYPEPTIDESNovember 2022February 2024Abandon1601NoNo
17998411JNK3 INHIBITORY PEPTIDESNovember 2022March 2026Allow4020NoNo
17981446Compositions and Method of Use for Hair Straightening and ShapingNovember 2022January 2025Allow2711NoNo
17997507PD-L1 BINDING PEPTIDESOctober 2022January 2026Allow3910NoNo
17920149ANTIBACTERIAL PROTEIN CDL200 HAVING LYTIC ACTIVITY AGAINST CLOSTRIDIOIDES DIFFICILEOctober 2022October 2025Allow3510NoNo
17965739CDKN2A COMPANION DIAGNOSTIC FOR BLADDER CANCER INTERFERON THERAPYOctober 2022August 2024Allow2221NoNo
17938624FORMULATIONS AND METHODS OF USE FOR ALPHA CONNEXIN C-TERMINAL (ACT) PEPTIDESOctober 2022June 2024Allow2021NoNo
17916778LIQUID PHARMACEUTICAL FORMULATIONS POLYETHYLENE GLYCOL-BASED PRODRUGS OF ADRENOMEDULLIN AND USEOctober 2022January 2026Abandon4001NoNo
17936956Beta-Arrestin Effectors and Compositions and Methods of Use ThereofSeptember 2022March 2026Abandon4101NoNo
17935726CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITIONSeptember 2022January 2024Allow1611NoNo
17946071CYCLOPHILIN INHIBITORS AND USES THEREOFSeptember 2022April 2024Allow1941NoNo
17906403PEPTIDE SYNTHESIS AND SYSTEM THEREOFSeptember 2022December 2025Allow3911YesNo
17911277PEPTIDE ANALOGS AND USE OF SAME IN TREATING DISEASES, DISORDERS OR CONDITIONS ASSOCIATED WITH MUTANT P53 PROTEINSeptember 2022March 2026Abandon4201NoNo
17943955SYNTHETIC PLATELETSSeptember 2022July 2024Allow2311NoNo
17910467NORRIN REGULATION OF PLASMALEMMA VESICLE-ASSOCIATED PROTEIN AND USE TO TREAT MACULAR DEGENERATIONSeptember 2022January 2026Abandon4001NoNo
17899634CELL-PENETRATING PEPTIDE DIMERS, METHOD FOR PREPARING THE SAME, AND CARGO DELIVERY SYSTEM USING THE SAMEAugust 2022July 2024Abandon2321NoNo
17898220CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITIONAugust 2022November 2023Allow1411NoNo
17820243PROTEINS WITH CARDIOPROTECTIVE ACTIVITYAugust 2022August 2024Allow2431YesNo
17817084Therapeutic Agent for PsoriasisAugust 2022March 2025Allow3221NoNo
17760081TARGETED PLASMA PROTEIN DEGRADATIONAugust 2022January 2026Allow4221NoNo
17879143METHODS FOR THE PREVENTION AND TREATMENT OF BURN INJURIES AND SECONDARY COMPLICATIONSAugust 2022February 2025Abandon3121NoNo
17795129COMPOSITIONS INCLUDING ANTIMICROBIAL POLYMER- PEPTIDE CONJUGATES AND USES THEREOFJuly 2022February 2026Allow4221NoNo
17864685COMPOSITION OF FISH SKIN COLLAGEN PEPTIDES AND USE THEREOF AS A DRUGJuly 2022July 2024Allow2431YesNo
17811470AGENT FOR PROMOTING ANGIOGENESIS AND METHODS AND USES THEREOFJuly 2022November 2023Abandon1701NoNo
17853839Technology for Modulating Targeting Chimeras Induced by Cell-Penetrating Peptide and Application ThereofJune 2022July 2024Abandon2411NoNo
17851959N-TERMINAL CAPPING MODULES OF ANKYRIN REPEAT DOMAINSJune 2022January 2024Allow1821YesNo
17842953GhR-BINDING PEPTIDE AND COMPOSITION COMPRISING SAMEJune 2022May 2025Allow3551NoNo
17843748Regenerative Polypeptides and Uses ThereofJune 2022March 2025Allow3311NoNo
17838766METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITHJune 2022May 2025Abandon3531NoNo
17830565NOVEL AMPHIPHILIC PEPTIDE CHAPERONES AND METHODS OF USEJune 2022October 2023Allow1621NoNo
17781022POLYPEPTIDE TAG AND APPLICATION THEREOF IN IN VITRO PROTEIN SYNTHESISMay 2022February 2026Allow4421YesNo
17824621AUTOPHAGY AS A THERAPEUTIC TARGET FOR INTRACRANIAL ANEURYSMMay 2022June 2024Allow2541NoYes
17778785A NEW ANTIBIOTIC SELECTIVELY KILLS GRAM-NEGATIVE PATHOGENSMay 2022January 2026Allow4421NoNo
17743321Polypeptides Related to HMGB1 Useful for Promoting Tissue Regeneration, Compositions Comprising Same, and Uses ThereofMay 2022January 2026Allow4411NoNo
17737714NOVEL PEPTIDEMay 2022November 2023Allow1811NoNo
17660969ANTIFUNGAL PROTEIN COMPOSITIONApril 2022September 2025Abandon4101NoNo
17771334METHODS FOR TREATING PATIENTS HAVING CFH MUTATIONS WITH RECOMBINANT CFH PROTEINSApril 2022December 2025Abandon4401NoNo
17724913POLYMER AGONISTS OF MU OPIOID RECEPTORSApril 2022July 2024Allow2721NoNo
17724927Methods and Compositions for Treatment of Antibiotic-Resistant Bacterial InfectionsApril 2022March 2025Allow3551YesYes
17767550CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOFApril 2022November 2025Allow4320NoNo
17658129INSECTICIDAL PROTEINS AND METHODS FOR THEIR USEApril 2022March 2025Abandon3541NoNo
17703770HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAMEMarch 2022December 2025Abandon4411NoNo
17701561COMPOUNDS AND COMPOSITIONS FOR MODULATING LISTERIA VIRULENCEMarch 2022May 2024Allow2631YesNo
17639082SYNTHETIC ANTIMICROBIAL PEPTIDESFebruary 2022October 2025Abandon4311NoNo
17633146COMPOSITIONS AND METHODS FOR TREATMENTFebruary 2022June 2025Allow4111NoNo
17586196CONDITIONALLY IMMORTALIZED LONG-TERM STEM CELLS AND METHODS OF MAKING AND USING SUCH CELLSJanuary 2022November 2023Abandon2201NoNo
17579237CONJUGATION OF MCR1 LIGAND WITH CYTOTOXIC DRUGS FOR TREATING SKIN CANCERJanuary 2022June 2025Allow4111NoNo
17627378NOVEL INHIBITORS OF KALLIKREIN PROTEASES AND USES THEREOFJanuary 2022November 2025Abandon4621NoNo
17569129ZWITTERIONIC POLYMER-INSULIN COMPOSITIONS AND RELATED METHODSJanuary 2022November 2024Allow3421NoYes
17568411DUAL IL-2R AND IL-7R BINDING COMPOUNDSJanuary 2022October 2024Abandon3431NoNo
17555392COMPOSITIONS AND METHOD OF USE FOR HAIR STRAIGHTENING AND SHAPINGDecember 2021October 2022Allow1021NoNo
17550306METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISORDERS AND ALZHEIMER'S DISEASE AND IMPROVING NORMAL MEMORYDecember 2021October 2023Abandon2201NoNo
17549579PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASESDecember 2021September 2025Allow4551YesNo
17546177RATIONALLY DESIGNED ANTIVIRAL COMPOUNDS THAT INHIBIT SARS-CoV-2 AND THEIR METHODS OF USE THEREOFDecember 2021August 2023Abandon2011NoNo
17545870TREATMENT OF PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING ELECTIVE SURGERY BY ADMINISTRATION OF RECOMBINANT VWFDecember 2021March 2026Allow5151NoYes
17543464Selective and Noncovalent Inhibitors of Oncogenic RAS MutantsDecember 2021March 2024Allow2731YesNo
17541619ANTI-KRAS-G12D T CELL RECEPTORSDecember 2021July 2023Allow2011NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner COFFA, SERGIO.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
7
Examiner Affirmed
6
(85.7%)
Examiner Reversed
1
(14.3%)
Reversal Percentile
25.6%
Lower than average

What This Means

With a 14.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
50
Allowed After Appeal Filing
10
(20.0%)
Not Allowed After Appeal Filing
40
(80.0%)
Filing Benefit Percentile
24.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner COFFA, SERGIO - Prosecution Strategy Guide

Executive Summary

Examiner COFFA, SERGIO works in Art Unit 1658 and has examined 343 patent applications in our dataset. With an allowance rate of 57.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.

Allowance Patterns

Examiner COFFA, SERGIO's allowance rate of 57.1% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by COFFA, SERGIO receive 2.70 office actions before reaching final disposition. This places the examiner in the 79% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by COFFA, SERGIO is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +30.9% benefit to allowance rate for applications examined by COFFA, SERGIO. This interview benefit is in the 79% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 14.4% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 37.2% of cases where such amendments are filed. This entry rate is in the 56% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 122.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 83% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 76.7% of appeals filed. This is in the 68% percentile among all examiners. Of these withdrawals, 69.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 89.7% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.3% of allowed cases (in the 55% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.0% of allowed cases (in the 61% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.